GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa

GLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology. These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrzb-Mikiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of